Alectinib vs Ceritinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Alectinib · Alecensa

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02075840 · Phase 3 · completed

Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)

Result source: NCT02838420

Ceritinib

Marketed by Novartis

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01828099 · Phase 3 · completed

The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).

Next expected readout: December 2026 · NCT02321501 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)

Result source: NCT01828099

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlectinibCeritinib
PFS, median10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results
OS, median81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results
ORR82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results
Duration of response, median42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results

PFS, median

Alectinib
10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
Ceritinib
16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results

OS, median

Alectinib
81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
Ceritinib
62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results

ORR

Alectinib
82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
Ceritinib
72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results

Duration of response, median

Alectinib
42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
Ceritinib
23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Alectinib: 10 of 10 rows · Ceritinib: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlectinib
Rows use multiple source trials
Ceritinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
82.7% (n=52) vs 25% (n=28) Premetrexed/Docetaxela,b,c
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
84.7% (n=189) vs 73.8% (n=187) Chemotherapyd,a,b,c
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more dose
89.4% (n=189) vs 75.9% (n=187) Chemotherapy
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control
responder rate · % of participants
No placebo or comparator arm
66.7% (n=87)600 mg (Fed)e,f,b,c
NCT01871805 · Phase 1/2 · registry result, not featured evidence
70% (n=20)e,f,b,c
NCT02450903 · Phase 2 · registry result, not featured evidence
2 other source trials
77.7% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
67% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
15.2 monthsg,h,b,c
NCT01801111 · Phase 1/2
2 other source trials
14.9 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
13.3 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
14.19 monthsd,g,h,b,c
NCT01283516 · Phase 1
show 1 more dose
21.75 months
NCT01283516 · Phase 1
ORR
responder rate · % of participants
No placebo or comparator arm
50.8% (n=122)d,g,h,b,c
NCT01801111 · Phase 1/2
show 5 more doses
44.8% (n=96)
NCT01801111 · Phase 1/2
73.1% (n=26)
NCT01801111 · Phase 1/2
51.4% (n=138)
NCT01801111 · Phase 1/2
50% (n=110)
NCT01801111 · Phase 1/2
57.1% (n=28)
NCT01801111 · Phase 1/2
73.5% (n=83)d,g,h,b,c
NCT01283516 · Phase 1
show 1 more dose
65.1% (n=83)
NCT01283516 · Phase 1
Overall Survival
time to event · months
No placebo or comparator arm
29.2 monthse,f,b,c
NCT01801111 · Phase 1/2
1 other source trial
27.9 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
17.3 monthse,f,b,c
NCT02450903 · Phase 2 · registry result, not featured evidence
3 other source trials
51.3 months
NCT01685138 · Phase 2 · registry result, not featured evidence
15.6 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
17.5 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
8.9 monthsg,h,b,c
NCT01801111 · Phase 1/2
2 other source trials
8.2 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
8.4 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
15.21 monthsd,g,h,b,c
NCT01283516 · Phase 1
show 1 more dose
19.32 months
NCT01283516 · Phase 1
Dropout rate
n/a: no completion milestonei
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
n/a: no completion milestone
NCT02838420 · Phase 3 · monotherapy
54.4%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestonej
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
n/a: no completion milestoneCeritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
n/a: no completion milestone750 mg
NCT01283516 · Phase 1
n/a: no completion milestone700 mg
NCT01283516 · Phase 1
n/a: no completion milestone600 mg
NCT01283516 · Phase 1
n/a: no completion milestone500 mg
NCT01283516 · Phase 1
n/a: no completion milestone400 mg
NCT01283516 · Phase 1
n/a: no completion milestone300 mg
NCT01283516 · Phase 1
n/a: no completion milestone200 mg
NCT01283516 · Phase 1
n/a: no completion milestone100 mg
NCT01283516 · Phase 1
n/a: no completion milestone50 mg
NCT01283516 · Phase 1
n/a: no completion milestone
NCT02450903 · Phase 2 · registry result, not featured evidence
74.2%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0%i
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
—
NCT02838420 · Phase 3 · monotherapy
—
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
8.7%
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
12.7%j
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
6.1%Ceritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
11%750 mg
NCT01283516 · Phase 1
0%700 mg
NCT01283516 · Phase 1
20%600 mg
NCT01283516 · Phase 1
0%500 mg
NCT01283516 · Phase 1
0%400 mg
NCT01283516 · Phase 1
0%300 mg
NCT01283516 · Phase 1
0%200 mg
NCT01283516 · Phase 1
0%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
15%
NCT02450903 · Phase 2 · registry result, not featured evidence
14.5%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
8.6%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
6.8%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Serious AEs
46.1%i
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
15.2%
NCT02838420 · Phase 3 · monotherapy
26%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
28.3%
NCT01801111 · Phase 1/2
24.1%600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
49.2%j
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
—Ceritinib
NCT01828112 · Phase 3 · monotherapy
49.6%Ceritinib (On-treatment)
NCT01828112 · Phase 3
56.9%750 mg
NCT01283516 · Phase 1
60%700 mg
NCT01283516 · Phase 1
70%600 mg
NCT01283516 · Phase 1
40%500 mg
NCT01283516 · Phase 1
50%400 mg
NCT01283516 · Phase 1
33.3%300 mg
NCT01283516 · Phase 1
33.3%200 mg
NCT01283516 · Phase 1
50%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
45%
NCT02450903 · Phase 2 · registry result, not featured evidence
—LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
40.3%LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
47.9%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
35%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
i
constipation 40.1%
anaemia 27.6%
blood bilirubin increased 24.3%
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
aspartate aminotransferase increased 52%
blood bilirubin increased 48.8%
blood creatine phosphokinase increased 44%
NCT02838420 · Phase 3 · monotherapy
constipation 20.8%
anaemia 15.6%
myalgia 14.3%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
constipation 38.4%
fatigue 31.2%
oedema peripheral 30.4%
NCT01801111 · Phase 1/2
600 mg (Fed)
fatigue 41.4%
constipation 39.1%
headache 28.7%
NCT01871805 · Phase 1/2 · registry result, not featured evidence
j
diarrhoea 84.7%
nausea 68.8%
vomiting 67.2%
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
diarrhoea 73%
nausea 63.5%
vomiting 53%
NCT01828112 · Phase 3
750 mg
diarrhoea 86.7%
nausea 84.3%
vomiting 62.4%
NCT01283516 · Phase 1
700 mg
nausea 100%
alanine aminotransferase increased 80%
diarrhoea 80%
NCT01283516 · Phase 1
600 mg
nausea 100%
diarrhoea 80%
fatigue 80%
NCT01283516 · Phase 1
500 mg
nausea 90%
diarrhoea 70%
dyspnoea 50%
NCT01283516 · Phase 1
400 mg
nausea 71.4%
diarrhoea 64.3%
vomiting 57.1%
NCT01283516 · Phase 1
300 mg
nausea 66.7%
abdominal pain 33.3%
anaemia 33.3%
NCT01283516 · Phase 1
200 mg
vomiting 100%
cough 66.7%
diarrhoea 66.7%
NCT01283516 · Phase 1
100 mg
asthenia 50%
axillary pain 50%
blood lactate dehydrogenase increased 50%
NCT01283516 · Phase 1
50 mg
dyspnoea 100%
blood lactate dehydrogenase increased 50%
bronchitis 50%
NCT01283516 · Phase 1
diarrhoea 85%
nausea 80%
vomiting 65%
NCT02450903 · Phase 2 · registry result, not featured evidence
diarrhoea 85.5%
nausea 78.2%
vomiting 71.8%
NCT01685138 · Phase 2 · registry result, not featured evidence
750 mg
diarrhoea 82.1%
nausea 82.1%
vomiting 65.7%
NCT01685060 · Phase 2 · registry result, not featured evidence
diarrhoea 74.8%
vomiting 61.2%
alanine aminotransferase increased 59.2%
NCT02040870 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: prior_therapy differs (naive versus experienced).
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 1/2.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gTrial phases differ: Phase 1 versus Phase 1/2.
  8. hPopulation context differs: registered conditions differ.
  9. iPopulation comparability has not been reviewed for 3 of these studies.
  10. jPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alectinib

CNS Progression 11.8% (n=152) vs 45% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
10.5% (n=152) vs 35.8% (n=151) Crizotinib
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS ORR 59.4% (n=152) vs 25.9% (n=151) Crizotinib
responder rate · % of participants
Measurable and non-measurable CNS lesions
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS DOR 17.3 vs 5.5 Crizotinib months
absolute value · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration C30 Dyspnoea NA vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Cough NA vs NA Crizotinib months
time to event · months
Coughing
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Dyspnea 22.8 vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Chest Pain NA vs NA Crizotinib months
time to event · months
Pain in chest
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Composite Symptoms 12.7 vs 21 Crizotinib months
time to event · months
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
LC13 Deterioration 32% (n=152) vs 28% (n=151) Crizotinib
ratio to baseline · % of baseline
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS ORR 66.7% (n=24) vs 0% (n=17) Premetrexed/Docetaxel
responder rate · % of participants
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 36.1% (n=79) vs 11.4% (n=40) Premetrexed/Docetaxel
responder rate · % of participants
Assessed by IRC
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 76.4% (n=79) vs 48.6% (n=40) Premetrexed/Docetaxel
responder rate · % of participants
Assessed by IRC
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

+ 625 further endpoints in the CSV export.

Ceritinib

Time to Response 1.42 vs 3.08 Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.14 weeks as posted
show 3 more results
1.45 vs 2.93 Chemotherapy months*
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.29 weeks as posted
1.55 vs 2.22 Chemotherapy months*
NCT01828112 · Phase 3 · monotherapy · converted to months from 6.71 weeks as posted
1.48 vs 3.39 Chemotherapy months*
NCT01828112 · Phase 3 · monotherapy · converted to months from 6.43 weeks as posted
Intracranial 72.7% (n=22) vs 27.3% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Disease Control 86.4% (n=22) vs 90.9% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Duration of Response 16.6 vs NA Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Response 3 months @ 24wk750 mg
time to event · months
No placebo or comparator arm
NCT01685060 · Phase 2 · registry result, not featured evidence
show 6 more results
2.2 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
1.8 months
NCT02450903 · Phase 2 · registry result, not featured evidence
2.5 months
NCT01685138 · Phase 2 · registry result, not featured evidence
2.2 months
NCT01685138 · Phase 2 · registry result, not featured evidence
1.9 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
1.8 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Intracranial ORR 45% (n=20) @ 24wk750 mg
responder rate · % of participants
No placebo or comparator arm
NCT01685060 · Phase 2 · registry result, not featured evidence
show 6 more results
35.7% (n=28) @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
0% (n=2)
NCT02450903 · Phase 2 · registry result, not featured evidence
20% (n=10)
NCT01685138 · Phase 2 · registry result, not featured evidence
61.5% (n=13)
NCT01685138 · Phase 2 · registry result, not featured evidence
39.1% (n=23)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
0% (n=9)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Disease Control 76.4% (n=140) @ 24wk750 mg
responder rate · % of participants
No placebo or comparator arm
DCR per Investigator
NCT01685060 · Phase 2 · registry result, not featured evidence
show 1 more result
90.3% (n=124)
DCR per Investigator
NCT01685138 · Phase 2 · registry result, not featured evidence
PFS 16.6 months
time to event · months
No placebo or comparator arm
PFS per Investigator
NCT01685138 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Ceritinib's landscape